ZNF134 is a zinc finger protein that functions as a transcriptional regulator, likely acting as a DNA-binding transcription repressor specific to RNA polymerase II 1. It exhibits sequence-specific DNA binding capability and participates in negative regulation of transcription, with potential roles in regulating immune system processes and cytokine production. At the molecular level, ZNF134 demonstrates protein binding activity and localizes to the nucleoplasm, consistent with its transcriptional regulatory function. The protein appears sensitive to epigenetic modification, as its expression is altered by DNA methylation status in disease contexts. ZNF134 has emerged as a significant biomarker across multiple disease contexts. In Parkinson's disease risk assessment, ZNF134 expression levels show negative correlation with disease severity scores, suggesting it may stratify individuals at risk prior to motor symptom onset 1. In diffuse large B-cell lymphoma with TET2 mutations, ZNF134 is hypermethylated and downregulated, identifying it as a key gene associated with lymphomagenesis and a potential diagnostic biomarker 2. Additionally, ZNF134 methylation status independently predicts survival outcomes in head and neck squamous cell carcinoma patients, with differential methylation associated with prognosis 3. A Mendelian randomization study indicates ZNF134 has a protective, negative association with osteoarthritis occurrence 4. Clinically, ZNF134's role as an epigenetically regulated gene with disease-specific methylation patterns positions it as a potential prognostic marker and therapeutic target across neurological, hematologic, and solid tumor malignancies.